R&D services platform will make it easier for researchers throughout the world to purchase InSphero assay ready models and services for drug efficacy and safety testing
Palo Alto, CA, USA and Schlieren, Switzerland − 6 November, 2019: Science Exchange, the world’s leading SaaS-enabled marketplace for outsourced R&D, and InSphero AG today announced a collaboration to facilitate access to InSphero’s comprehensive portfolio of pharma-validated 3D microtissues and assay services for drug discovery and safety testing. Under this agreement, InSphero solutions for liver toxicology safety assessments as well as screening platforms for metabolic disease and oncology research, will be available to scientists around the world through Science Exchange.
Over the past 10 years, InSphero-driven innovation has shaped the field of 3D cell-based assays and organ-on-a-chip technology, and the company has earned a reputation as the market leader in 3D cell-based solutions, shipped directly to labs ready to assay for pharmaceutical and biotech R&D. The uniformity, robustness and unrivaled biological relevance of its scaffold-free 3D microtissues have set the standard for drug-induced liver injury (DILI) safety testing as well 3D in vitro models for the study of oncology and metabolic diseases, such as diabetes, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).
InSphero 3D InSight™ Discovery and Safety Platforms have been precisely engineered to include the relevant primary human cell types in co-culture required to recapitulate even complex biological mechanisms faithfully in vitro. To drive efficient innovation throughout all phases of drug development, the scalable Akura™ plate technology underlying the company’s 3D InSight™ platforms includes automation-compatible, SBS-standard 96- and 384-well plate formats and the unique Akura™ Flow organ-on-a-chip system.
“Since we founded the company in 2009, our goal has been to make our 3D cell technology readily available to researchers around the globe. Our patent-pending logistics technology, highly skilled customer service team, and industry-grade 3D assay technology have fueled the rapid growth of our customer base over the past several years. Our partnership with Science Exchange is an important step toward making access to our technology even easier, so we can focus on what we do best: enabling our customers and partners to develop better, safer drugs, faster,” says InSphero CEO and co-founder Jan Lichtenberg, PhD.
The top-performing experts and tips for R&D success — all in one book.
Learn which CROs, CMOs, and academic labs performed best in frequently requested categories, such as chemical synthesis and nucleic acid services. We’ve aggregated data from our platform to bring you a resource to help you Change Science™.
InSphero is the pioneer of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology. Through partnerships, InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding the human physiology in vitro. Its robust and precisely engineered suite of 3D InSight™ human tissue platforms are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. The company specializes in liver toxicology, metabolic diseases (e.g., T1 & T2 diabetes and NAFLD & NASH liver disease), and oncology (with a focus on immuno-oncology and PDX models). The scalable Akura™ technology underlying the company’s 3D InSight™ Discovery and Safety Platforms includes 96 and 384-well plate formats and the Akura™ Flow organ-on-a-chip system to drive efficient innovation throughout all phases of drug development.
To learn more about InSphero on Science Exchange, visit: https://www.scienceexchange.com/labs/insphero